Teva launches its version of erythromycin and Absorica

Christine Blank

Teva is making the first generic version of Absorica (isotretinoin), a drug for the treatment of severe acne.

Teva Pharmaceuticals is launching a generic version of Erythromycin (Arbor Pharmaceuticals), an antibiotic that treats bacterial infections and prevents rheumatic fever attacks in patients allergic to penicillin.

Erythromycin oral tablets boast annual sales of more than $49 million in the U.S., according to IQVIA data, Teva said in a press release.The generic Erythomycin will be available in 250 mg and 500 mg tablets.

Related:FDA clears first treatment for severe hypoglycemia

The pharma maker is also rolling out the first generic of Absorica (isotretinoin) to treat severe recalcitrant nodular acne in patients 12 years and older with multiple inflammatory nodules with a diameter of 5 mm or greater.

Available dosage strengths include 10 mg, 20 mg, 25 mg, 30 mg. and 40 mg.

Related:Sandoz to supply critical generic injectable meds

“Teva’s first-to-market generic version of Absorica (isotretinoin) capsules in the U.S. is an important treatment option for patients living with severe recalcitrant nodular acne, and who are unresponsive to conventional acne therapy including antibiotics,” said Christine Baeder, senior vice president, chief operating officer US Generics, Teva USA, in a press release.

Isotretinoin oral capsules have annual sales of more than $158 million in the U.S., according to IQVIA data.

Read more:Express Scripts accused of overcharging millions of dollar